WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

New partnerships and contracts expected to bring in over $1 million in near-term R&D/milestone revenue and generate long term commercial revenue SUNNYVALE, Calif., Aug. 8, 2023 /PRNewswire/ – Willow Biosciences Inc. (“Willow”) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company…

Click here to view original post